Active Recombinant Human SLAMF7, Fc-tagged, Biotinylated
Cat.No. : | SLAMF7-688H |
Product Overview : | The recombinant human SLAMF7-Fc fusion protein is expressed as a 432-amino acid protein consisting of Ser23 - Met2250 region of SLAMF7 (UniProt accession #Q9NQ25) and a C-terminal Fc from human IgG1, which exists as a dimer under non-reducing conditions. |
- Specification
- Gene Information
- Related Products
- Download
Source : | Human cells |
Species : | Human |
Tag : | Fc |
Form : | Supplied at 0.5 mg/ml in sterile PBS pH7.4 (carrier & preservative free). The purified recombinant protein was labeled with Biotin (3-5 Biotin per molecule). |
Bio-activity : | Immobilized SLAMF7 interacts homophilically with SLAMF7 in a functional ELISA |
Molecular Mass : | Calculated molecular mass (kDa): 48.0; Estimated by SDS-PAGE under reducing condition (kDa): 60-70 |
AA Sequence : | SGPVKELVGSVGGAVTFPLKSKVKQ VDSIVWTFNTTPLVTIQPEGGTIIV TQNRNRERVDFPDGGYSLKLSKLKK NDSGIYYVGIYSSSLQQPSTQEYVL HVYEHLSKPKVTMGLQSNKNGTCVT NLTCCMEHGEEDVIYTWKALGQAA NESHNGSILPISWRWGESDMTFICV ARNPVSRNFSSPILARKLCEGAADD PDSSMSTGTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSPGK |
Endotoxin : | <0.1 eu per 1 μg of purified recombinant protein determined by the lal>0.1> |
Purity : | >95% judged by SDS-PAGE under reducing condition |
Storage : | The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks. Avoid repeated freeze-thaw cycles. |
Protein length : | Ser23-Met2250 |
Gene Name : | SLAMF7 SLAM family member 7 [ Homo sapiens ] |
Official Symbol : | SLAMF7 |
Synonyms : | SLAMF7; SLAM family member 7; 19A; CD319; CRACC; CS1; protein 19A; CD2 subset 1; 19A24 protein; membrane protein FOAP-12; CD2-like receptor activating cytotoxic cells; CD2-like receptor-activating cytotoxic cells; novel LY9 (lymphocyte antigen 9) like protein; |
Gene ID : | 57823 |
mRNA Refseq : | NM_021181 |
Protein Refseq : | NP_067004 |
MIM : | 606625 |
UniProt ID : | Q9NQ25 |
Chromosome Location : | 1q23.1-q24.1 |
Function : | receptor activity; |
Products Types
◆ Recombinant Protein | ||
SLAMF7-2328H | Recombinant Human SLAMF7 protein(Met1-Met226), hFc-tagged, Biotinylated | +Inquiry |
SLAMF7-121H | Recombinant Human SLAMF7 Protein, His-tagged | +Inquiry |
SLAMF7-0692H | Recombinant Human SLAMF7 protein, hFc-tagged | +Inquiry |
SLAMF7-2018H | Recombinant Human SLAMF7 Protein, His (Fc)-Avi-tagged | +Inquiry |
SLAMF7-449H | Recombinant Full Length Human SLAMF7 Protein, Fc-tagged | +Inquiry |
◆ Lysates | ||
SLAMF7-2378HCL | Recombinant Human SLAMF7 cell lysate | +Inquiry |
SLAMF7-2591MCL | Recombinant Mouse SLAMF7 cell lysate | +Inquiry |
Related Gene
Not For Human Consumption!
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewIt has a high solubility and can be easily prepared at the desired concentration.
It was found to be well active and could effectively perform the required biological activity experiments.
It was observed that SLAMF7 had good crystallinity, which was conducive to crystallography research.
Q&As (6)
Ask a questionSLAMF7 protein is involved in regulating immune cell activation, proliferation, and transmission of background signals by binding to activating ligands, such as CD319, thereby influencing the immune response.
By combining with immunotherapy, such as anti-PD-1 antibodies, the immune response can be further enhanced and the anti-tumor effect can be improved. The study of SLAMF7 protein provides a new direction for the development of combinatorial therapeutic strategies.
This protein is mainly expressed in the immune system, including immune cells such as plasma cells, NK cells, and activated T cells.
The role of SLAMF7 protein in other types of cancer is unclear, and further research is needed to determine its potential role in other cancers.
Yes, the SLAMF7 protein has been shown to be a potential therapeutic target. A monoclonal antibody drug targeting SLAMF7 protein (Elotuzumab) has been developed for the treatment of multiple myeloma.
SLAMF7 protein interacts with NK cells in multiple myeloma and plays a role in inhibiting and controlling tumor growth by activating the anti-tumor activity of NK cells.
Ask a Question for All SLAMF7 Products
Required fields are marked with *
My Review for All SLAMF7 Products
Required fields are marked with *
Inquiry Basket